全文获取类型
收费全文 | 209567篇 |
免费 | 21323篇 |
国内免费 | 11093篇 |
专业分类
耳鼻咽喉 | 2094篇 |
儿科学 | 3396篇 |
妇产科学 | 3628篇 |
基础医学 | 18013篇 |
口腔科学 | 4466篇 |
临床医学 | 26918篇 |
内科学 | 27992篇 |
皮肤病学 | 2676篇 |
神经病学 | 8589篇 |
特种医学 | 7667篇 |
外国民族医学 | 40篇 |
外科学 | 20522篇 |
综合类 | 40122篇 |
现状与发展 | 33篇 |
一般理论 | 18篇 |
预防医学 | 20052篇 |
眼科学 | 4402篇 |
药学 | 22001篇 |
228篇 | |
中国医学 | 14650篇 |
肿瘤学 | 14476篇 |
出版年
2024年 | 652篇 |
2023年 | 2883篇 |
2022年 | 6005篇 |
2021年 | 8727篇 |
2020年 | 7048篇 |
2019年 | 5222篇 |
2018年 | 5974篇 |
2017年 | 6340篇 |
2016年 | 5420篇 |
2015年 | 8872篇 |
2014年 | 11220篇 |
2013年 | 12826篇 |
2012年 | 17298篇 |
2011年 | 18387篇 |
2010年 | 14487篇 |
2009年 | 12571篇 |
2008年 | 13850篇 |
2007年 | 13515篇 |
2006年 | 12476篇 |
2005年 | 10691篇 |
2004年 | 7625篇 |
2003年 | 6687篇 |
2002年 | 5472篇 |
2001年 | 4830篇 |
2000年 | 4025篇 |
1999年 | 3221篇 |
1998年 | 1709篇 |
1997年 | 1625篇 |
1996年 | 1387篇 |
1995年 | 1276篇 |
1994年 | 1145篇 |
1993年 | 750篇 |
1992年 | 1046篇 |
1991年 | 927篇 |
1990年 | 786篇 |
1989年 | 711篇 |
1988年 | 650篇 |
1987年 | 547篇 |
1986年 | 465篇 |
1985年 | 380篇 |
1984年 | 261篇 |
1983年 | 246篇 |
1982年 | 158篇 |
1981年 | 160篇 |
1980年 | 112篇 |
1979年 | 164篇 |
1978年 | 136篇 |
1977年 | 119篇 |
1974年 | 99篇 |
1972年 | 100篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
4.
Zeyu Li Erwei Hao Rui Cao Si Lin Linghui Zou Tianyan Huang Zhengcai Du Xiaotao Hou Jiagang Deng 《中草药(英文版)》2022,14(4):479-493
Zedoary tumeric (Curcumae Rhizoma, Ezhu in Chinese) has a long history of application and has great potential in the treatment of liver cancer. The anti liver cancer effect of zedoary tumeric depends on the combined action of multiple pharmacodynamic substances. In order to clarify the specific mechanism of zedoary tumeric against liver cancer, this paper first analyzes the mechanism of its single pharmacodynamic substance against liver cancer, and then verifies the joint anti liver cancer mechanism of its "pharmacodynamic group". By searching the research on the anti hepatoma effect of active components of zedoary tumeric in recent years, we found that pharmacodynamic substances, including curcumol, zedoarondiol, curcumenol, curzerenone, curdione, curcumin, germacrone, β-elemene, can act on multi-target and multi-channel to play an anti hepatoma role. For example, curcumin can regulate miR, GLO1, CD133, VEGF, YAP, LIN28B, GPR81, HCAR-1, P53 and PI3K/Akt/mTOR, HSP70/TLR4 and NF-κB. Wnt/TGF/EMT, Nrf2/Keap1, JAK/STAT and other pathways play an anti hepatoma role. Network pharmacological analysis showed that the core targets of the "pharmacodynamic group" for anti-life cancer are AKT1, EGFR, MAPK8, etc, and the core pathways are neuroactive live receiver interaction, nitrogen metabolism, HIF-1 signaling pathway, etc. At the same time, by comparing and analyzing the relationship between the specific mechanisms of pharmacodynamic substance and "pharmacodynamic group", it is found that they have great reference significance in target, pathway, biological function, determination of core pharmacodynamic components, formation of core target protein interaction, in-depth research of single pharmacodynamic substance, increasing curative effect and so on. By analyzing the internal mechanism of zedoary tumeric pharmacodynamic substance and "pharmacodynamic group" in the treatment of liver cancer, this paper intends to provide some ideas and references for the deeper pharmacological research of zedoary tumeric and the relationship between pharmacodynamic substance and "pharmacodynamic group". 相似文献
6.
7.
Her-Shyong Shiah Nai-Jung Chiang Chia-Chi Lin Chia-Jui Yen Hui-Jen Tsai Shang-Yin Wu Wu-Chou Su Kwang-Yu Chang Ching-Chiung Wang Jang-Yang Chang Li-Tzong Chen 《The oncologist》2021,26(4):e567-e579
Lessons Learned
- SCB01A is a novel microtubule inhibitor with vascular disrupting activity.
- This first‐in‐human study demonstrated SCB01A safety, pharmacokinetics, and preliminary antitumor activity.
- SCB01A is safe and well tolerated in patients with advanced solid malignancies with manageable neurotoxicity.
8.
Depeng Meng Yichen Meng Bingyang Li Guigang Zeng Bin Zhang Chunlin Hou Haodong Lin Yueping Ouyang 《Journal of orthopaedic science》2021,26(3):409-414
BackgroundComminuted patellar fractures are not rare, and the ideal treatment method remains controversial. The present study was conducted to evaluate effects and compare complications of two different methods used to treat comminuted patellar fractures.MethodsFrom March 2010 to August 2016, 102 cases of 34-C2 or 34-C3 comminuted patellar fractures were treated at our hospital, wherein patients received two different treatments: titanium cable tension band with cerclage method (group A) and intrafragmentary screws with X-shaped plating technique (group B). At follow-ups, articular step-off, range of motion (ROM), Lysholm scores, time of union, and complications were recorded and analyzed. Radiographic and clinical data as well as rate of complications were statistically analyzed.ResultsIn total, 87 patients were included in the final analysis (n = 47 in group A and n = 40 in group B). No significant differences were noted in terms of cost of implant, age, gender, rate of 34-C3 fractures, rate of layered inferior pole fractures, postoperative articular step-off and union time. At 2-year follow-up, average Lysholm scores, ROM and rate of complications were (89.0 ± 4.5), (122°±12°) and (27.7%) in group A and (90.2 ± 3.9), (124°±11°) and (17.5%) in group B, respectively, with no significant differences (p > 0.05). The mean time of surgery in group B was shorter than that in group A with significant difference (p < 0.05).ConclusionsTreatment using the intrafragmentary screws and plate method for amenable comminuted patellar fractures achieved similar complication rate and favorable functional outcomes at the 2-year follow-up, which was comparable to the titanium cable tension band with cerclage method. Thus, the intrafragmentary screws and plate method is effective, safe and convenient for 34-C2/C3 comminuted patellar fractures, especially appropriate for patients with layered fragments. 相似文献
9.
10.
目的:建立UPLC-MS/MS分析方法同时测定玳玳果黄酮降脂提取物效应组分新橙皮苷和柚皮苷在大鼠10种脏器组织中含量,分布规律及特征。方法:采用UPLC-MS/MS技术建立提取物效应组分新橙皮苷及柚皮苷在大鼠心、肝、脾、肺、肾、脑、胃、小肠、脂质、肌肉组织中的定量分析方法;大鼠给药后分别于0.33,0.67,1,4,8 h的5个时间点,分别摘取以上10种脏器组织,测定脏器组织及血液中效应组分的质量浓度,采用DAS(V 2.0)药动学软件对各样本的药物浓度-时间数据进行房室拟合,并计算不同组织效应组分的药-时曲线下面积(AUC)及平均滞留时间(MRT)。结果:所建立的UPLC-MS/MS定量分析方法具备良好的专属性、标准曲线及线性范围良好、方法准确度与精密度、定量下限均符合有关规定;玳玳果黄酮降脂提取物效应组分在血液中的分布符合一室模型,除肾脏及脑组织外,其余脏器中提取物效应组分的房室特征多为静脉注射的二室模型,柚皮苷在肾脏中的拟合结果为非静脉注射的二室模型,新橙皮苷在脑组织拟合结果为静脉注射的三室模型,给药后8 h各组织中效应组分新橙皮苷及柚皮苷AUC值大小顺序均为小肠 > 胃 > 肾 > 脂质 ≈ 脾脏 > 肺 > 肌肉 > 肝 > 心 > 脑,效应组分在各脏器中均无明显蓄积;效应组分在血液、肾脏、肝脏中的滞留时间较长,MRT均大于2 h,脂质最短,MRT不足1 h;各脏器中新橙皮苷的药-时曲线下面积约是柚皮苷的3倍,而心、肝、肾中则是3.5,2.1和3.4倍。结论:玳玳果黄酮降脂提取物效应组分在大鼠组织中分布迅速,达峰时间早于血液;效应组分在肠道内消除缓慢,给药8 h后在各脏器中的含量均显著下降且无特异的蓄积部位。研究结果揭示玳玳果黄酮降脂提取物效应组分在大鼠体内的分布特征及规律,为进一步理解玳玳果黄酮降脂提取物在体内的作用靶点及机制奠定了基础。 相似文献